Department of Geriatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (C.F., M.G., S.H., Z.W.).
Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University, China (X.Y.).
Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2360-2375. doi: 10.1161/ATVBAHA.120.314278. Epub 2020 Aug 13.
Platelet activation by stimulatory factors leads to an increase in intracellular calcium concentration ([Ca]), which is essential for almost all platelet functions. Modulation of Ca influx and [Ca] in platelets has been emerging as a possible strategy for preventing and treating platelet-dependent thrombosis. Voltage-gated potassium 1.3 channels (Kv1.3) are highly expressed in platelets and able to regulate agonist-evoked [Ca] increase. However, the role of Kv1.3 channels in regulating platelet functions and thrombosis has not yet been elucidated. In addition, it is difficult to obtain a specific blocker for this channel, since Kv1.3 shares identical drug-binding sites with other K channels. Here, we investigate whether specific blockade of Kv1.3 channels by monoclonal antibodies affects platelet functions and thrombosis. Approach and Results: In this study, we produced the anti-Kv1.3 monoclonal antibody 6E12#15, which could specifically recognize both human and mouse Kv1.3 proteins and sufficiently block Kv1.3 channel currents. We found Kv1.3 blockade by 6E12#15 inhibited platelet aggregation, adhesion, and activation upon agonist stimulation. In vivo treatment with 6E12#15 alleviated thrombus formation in a mesenteric arteriole thrombosis mouse model and protected mice from collagen/epinephrine-induced pulmonary thromboembolism. Furthermore, we observed Kv1.3 regulated platelet functions by modulating Ca influx and [Ca] elevation, and that this is mediated in part by P2X. Interestingly, mice showed impaired platelet aggregation while displayed no abnormalities in in vivo thrombus formation. This phenomenon was related to more megakaryocytes and platelets produced in mice compared with wild-type mice.
We showed specific inhibition of Kv1.3 by the novel monoclonal antibody 6E12#15 suppressed platelet functions and platelet-dependent thrombosis through modulating platelet [Ca] elevation. These results indicate that Kv1.3 could act as a promising therapeutic target for antiplatelet therapies.
刺激因子引起的血小板激活会导致细胞内钙离子浓度([Ca])增加,这对于几乎所有的血小板功能都是必不可少的。调节血小板内 Ca 流入和[Ca]的变化已经成为预防和治疗血小板依赖性血栓形成的一种可能策略。电压门控钾 1.3 通道(Kv1.3)在血小板中高度表达,能够调节激动剂诱导的[Ca]增加。然而,Kv1.3 通道在调节血小板功能和血栓形成中的作用尚未阐明。此外,由于 Kv1.3 与其他 K 通道共享相同的药物结合位点,因此很难获得该通道的特异性阻断剂。在这里,我们研究了特异性阻断 Kv1.3 通道的单克隆抗体是否会影响血小板功能和血栓形成。方法和结果:在这项研究中,我们制备了能够特异性识别人和鼠 Kv1.3 蛋白的抗 Kv1.3 单克隆抗体 6E12#15,并能充分阻断 Kv1.3 通道电流。我们发现,6E12#15 阻断 Kv1.3 可抑制激动剂刺激下的血小板聚集、黏附和激活。体内用 6E12#15 治疗可减轻肠系膜小动脉血栓形成小鼠模型中的血栓形成,并可保护小鼠免受胶原/肾上腺素诱导的肺血栓栓塞。此外,我们观察到 Kv1.3 通过调节 Ca 流入和[Ca]升高来调节血小板功能,而这部分是由 P2X 介导的。有趣的是,与野生型小鼠相比, 小鼠的血小板聚集受损,但体内血栓形成无异常。这种现象与 小鼠产生的巨核细胞和血小板比野生型小鼠更多有关。结论:我们通过新型单克隆抗体 6E12#15 特异性抑制 Kv1.3,通过调节血小板[Ca]升高来抑制血小板功能和血小板依赖性血栓形成。这些结果表明 Kv1.3 可以作为抗血小板治疗的一个有前途的治疗靶点。